How To Prove whether or not One Dose Of A COVID-19 Vaccine Could Save Lives A vaccine dose is better than none, right? Well, that depends.
On December 30th, the UK approved its second vaccine, one that was developed by Oxford University and pharmaceutical company AstraZeneca. The UK government also announced that from now on it means that as many people as possible will be vaccinated with their first dose, even if they have to wait up to 12 weeks to get their second. UK officials justify this, although it may be better that anyone who gets a second dose right away and distributes the doses can save more lives.
President-elect Joe Biden also plans to change the U The policy of withholding a second dose for each person receiving a first dose. Although the time between doses remains the same, the strategy runs the risk of delaying a second dose if production can’t keep up.
It is currently unclear how effective these strategies would be. Although there are other multiple-dose vaccines out there that recommend at least one dose in some cases and two in others, the diseases they prevent and the themselves are vastly different from those for COVID- there is some evidence that a single dose of the new this medicine could be effective in protecting people for 12 weeks between doses or possibly longer, but these predictions are based on either calculations or subsets of data.
To know for sure whether a single dose of a COVID-19 vaccine is effective either alone or with a long delay before the second dose compared to a shorter time, scientists would need to conduct more clinical trials; trials would be crucial; An effective single dose given twice as many people can save lives.
The first question is how long can one wait between doses? With other vaccines, like the HPV vaccine, a longer time between doses actually makes the vaccine more effective after both doses. However, there are no specific data for a COVID-19 vaccine on how delaying the second dose might affect the effectiveness of the vaccine after the second dose.
Then the question arises whether a single dose can work on its own Oxford-AstraZeneca vaccine, only approved in the UK, has two doses, as well as two approved in both US. and Great Britain: one from pharmaceutical companies Pfizer and BioNTech and one from biotech company Moderna.
While most Oxford-AstraZeneca participants in the UK study waited between nine and 12 weeks for a second dose of the vaccine, no recent study has independently investigated the study as to whether a single dose of the vaccine would be effective for even twelve weeks. For the other two vaccines, the scientists didn’t test that long delay between doses. For the Pizer and BioNTech vaccine, a second dose is given three weeks after the First, while Moderna’s second vaccine dose is given after four weeks.
The first dose of all of these COVID-19 vaccines is the primary shot. The second reintroduces the virus so the immune system can better remember how to respond. For a first dose on its own to be effective, scientists would need to demonstrate that a second dose is not needed to “jog” memory on the immune system.
UK officials emphasize that anyone who receives a first dose of the vaccine will be within 12 weeks receives a second, but many infectious disease experts are still questioning the strategy. Dr. Anthony Fauci, the top infectious disease expert in the United States, told CNN that he was “not in favor of” the UK strategy.
“We want to stick with what science tells us,” he said. At the moment, the two US-approved this medicine are most effective with three or four weeks between doses. “We don’t know how effective this first dose is without the second based on the clinical trial,” says Mark Cameron, immunologist at Case Western Reserve University.
So far, the data suggest that the Pfizer BioNTech vaccine is 52-effective after the first dose, although this was only based on a subset of people who contracted the virus days between the two shots in the study ( some of whom received the vaccine). The UK Joint Committee on Vaccination and Immunization has stated that the Pfizer BioNTech vaccine could provide around 90% protection in the short term. The Oxford-AstraZeneca was 73 years old – effective in a subset of study participants after a shot.
Although it is unclear how the UK found a 90-fold rate for the Pfizer BioNTech vaccine, some infectious disease experts have a similar 80- to 90 times the rate determined. Both doses of the Vacuum Cine have a delayed effect, so experts obtained this higher rate by studying how effective the vaccine was shortly after the second dose, when the first dose is believed to have been effective but the second not yet . In Moderna’s three studies, the vaccine appeared to be effective in 80 to 90% of approximately 2,000 participants.